New Eye Drops Show Promise for Improving Night Vision in Clinical Trials
New eye drops developed by Opus Genetics have shown encouraging results in improving night vision among people who experience difficulty seeing clearly in low-light conditions, according to findings from two late-stage clinical studies.
The treatment is being evaluated for people who experience problems such as glare, halos and starbursts, which can make driving at night particularly challenging.
Clinical Trial Shows Improvement in Night Vision
The first Phase III study involved 145 participants who reported difficulty seeing in dim or dark environments.
Participants were given either 0.75% phentolamine ophthalmic solution or a placebo for eight or 15 days.
After eight days, 13% of patients receiving the eye drops improved by at least three lines on an eye chart, compared with 3% among those who received the placebo.
The difference increased by the 15-day mark. Around 21% of patients in the treatment group achieved the same level of improvement, while the placebo group remained at 3%.
Participants using the eye drops also reported improvements in problems associated with night vision, including glare, halos and starbursts.
By the 15th day, researchers reported a statistically significant improvement in overall night-vision difficulties among those receiving the treatment.
How the Eye Drops May Work
According to the researchers, the eye drops work by affecting a muscle in the iris, resulting in moderate constriction of the pupil.
This effect can reportedly continue for at least 20 hours, potentially helping control the amount of light entering the eye during low-light conditions.
A significant number of participants in the study had developed night-vision problems following procedures such as LASIK surgery.
Second Study Shows Encouraging Results
Opus Genetics has also reported positive early findings from a second Phase III clinical trial.
The company said participants demonstrated improved ability to see road conditions when facing the glare of oncoming headlights. Improvements were also reported when dealing with glare during dawn and dusk.
These findings could be particularly relevant for people whose night-driving difficulties are linked to excessive glare or changes in pupil behaviour.
FDA Grants Fast Track Designation
The US Food and Drug Administration (FDA) has granted Fast Track designation to the eye drops for the treatment of chronic night-driving impairment.
Fast Track status is intended to facilitate the development and regulatory review of treatments addressing serious conditions where there is an unmet medical need. However, the designation does not mean that the treatment has been approved.
Further regulatory review will be required before the eye drops can potentially become widely available.
The clinical results so far suggest that phentolamine ophthalmic solution could become a potential treatment option for people experiencing persistent night-vision difficulties, particularly those affected by glare and other low-light visual problems.
